← Leaderboards
Donald R Gehlert
Epiodyne, Inc.
$6,552,597
Attributed
$13,105,194
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2019–23$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$13,105,194 · 3
By mechanism
UG3$6,461,202 · 1
UH3$4,143,992 · 1
R44$2,500,000 · 1
Top collaborators
- William K Schmidt5 shared
Most similar at Epiodyne, Inc.
Same institution · by research overlap
- William K Schmidt$6,552,597
- Julio Medina$300,000
Others in their field
Other Emerging Leaders on “Opioid”
- Chanza Baytop · Westat, Inc.$271,217,917
- Eve Jelstrom · The Emmes Company, Llc$36,024,078
- Jeffrey Reich · Sparian Biosciences, Inc.$28,894,251
- Xinhua Li · Nano Terra, Inc.$24,102,307
- Andrew S Huhn · Johns Hopkins University$19,514,484
- Emmanuel Aja Oga · Research Triangle Institute$17,470,090
Research focus
OpioidLigandsPharmaceutical PreparationsAgonistMu Opioid ReceptorsBuprenorphineScaffoldOralRespiratoryRattusPropertySeriesVentilatory DepressionDangerousnessMedicalAbuse LiabilityTherapeutic OpioidCessation Of LifeLeadOverdoseAdoptionAnhedoniaDependenceAnguish
Grant awards (5)
Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings$1,549,446
UH3 · FY2023 · DA · contact PI
Development of an oral analgesic with reduced liabilities$1,488,866
R44 · FY2023 · DA · contact PI
Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings$2,594,546
UH3 · FY2022 · DA · contact PI
Development of an oral analgesic with reduced liabilities$1,011,134
R44 · FY2022 · DA · contact PI
Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings$6,461,202
UG3 · FY2019 · DA · contact PI